Abstract: The method comprises a first stage of formation of a batch of a specific number of full containers to be emptied, which are then subjected to an operation of external washing by spraying with hot, de-ionized water and a subsequent rinsing operation, likewise by spraying with de-ionized water, passing then to a step of drying of the containers and afterwards to a step of cutting off one end of the containers, which then pass to a gripping step, in the same number of containers that were arranged in the batch at the start of the method, these being inverted to permit the fall and collection of the masses of plasma.

Abstract: The apparatus comprises a casing which envelopes a set of drive and control members and is provided with supports for containers holding the medicinal starting solutions and containers for the medicinal output solutions, and is characterized in that it comprises means for supporting and locating a unit for the suction and expulsion of the solutions, combined with a distributor for defining the liquid inlets and outlets, the apparatus having means for the closure of the flexible inlet and outlet tubes of the distributor by pinching and means for actuating the device for the suction and expulsion of solutions, as well as means for the programmed control of the operating cycles of the means for the closure of the flexible tubes by pinching, with means for the input of operational instructions by a keyboard or the like.

Abstract: The invention is based on the use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia, comprising the preparation of therapeutic concentrates of alpha-1 antitrypsin, in any form of administration tolerated by humans, the alpha-1 antitrypsin being obtained by purification of human plasma or being produced by recombinant or transgenic technology, with doses equal to or greater than 6 mg of alpha-1 antitrypsin per kg of body weight for a variable period of time.

Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterised in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.

Abstract: Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin. The composition comprises a concentrate of FVIII, of vWF or of FVIII/vWF complex of human origin with a chelating agent for metals, a specific ligand and preferably a protease inhibitor.

Abstract: The gammaglobulin is extracted from a fraction isolated by fractionation with ethanol in the presence of a carbohydrate, and after reducing the content of contaminants with PEG, it is applied to an anionic resin exchange column, an effluent being obtained in which the PEG content is subsequently reduced by ultrafiltration and which is concentrated in order to carry out sequentially an optional treatment at an acid pH and at least one of the following steps of viral inactivation, consisting of pasteurisation and a treatment with solvent/detergent, the product afterwards being precipitated and washed with PEG in order to eliminate any chemical viral inactivation reagents and then, by solubilisation and change of pH, the protein contaminants, and finally purified by ultrafiltration to reduce the volume and the PEG content, then carrying out an optional virus filtration and subsequent concentration.

Abstract: A method for sterile dosing of vials comprises a step for fitting stopper and cap assemblies together and washing vials. The stopper/cap assembly is then fitted with its external protector and a step of sterilization in an autoclave under vacuum is then performed. A subsequent step of cooling in laminar airflow to prevent the entry of air and dosing and plugging are then performed with continuous display of the operation and taking of views with a video camera. Followed by encapsulation and re-plugging, step of marking of the glass of the vial by means of laser beams to identify time and dosing information is performed.

Abstract: The method comprises viewing by of a magnetic recording camera the zone for the opening of vials and for metered filling thereof and continuously recording the zones visually during the operation of the installation and simultaneously carrying out the identification marking of each full glass container, with indelible marking means, at the outlet of the installation.

Abstract: The process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters to a pore size smaller than 35 nm.

Abstract: The method comprises a step for fitting stopper and cap assemblies together and washing vials; the stopper/cap assembly is then fitted with its external protector and a step of sterilization in an autoclave under vacuum is then performed, with a subsequent step of cooling in a laminar air-flow to prevent the entry of air; dosing and plugging are then performed with continuous display of the operation and taking of views with a video camera or the like, followed by encapsulation and re-plugging, with marking of the glass of the vial by means of laser beams to identify time and dosing information.

Abstract: The gripping device comprises in a single retaining frame a plurality of gripper units for gripping the bottles to be emptied, each of which units comprises, mating with the lateral profile of a bottle, a fixed member and a movable member, capable of fitting round a part of the outer surface of the bottle to be emptied, each of the gripper units having associated with it a device for piercing the bottle, equipped with a piercing member for the introduction of an expulsion gas and drainage of the contents of the bottle, and also an optical sensor for checking the presence of the bottle and checking whether there are contents therein.

Abstract: The method comprises viewing by means of a magnetic recording camera the zone for the opening of vials and for metered filling thereof and continuously recording said zones visually during the operation of the installation and simultaneously carrying out the identification marking of each full glass container, with indelible marking means, at the outlet of the installation.

Abstract: The method comprises a first stage of formation of a batch of a specific number of full containers to be emptied, which are then subjected to an operation of external washing by spraying with hot, de-ionised water and a subsequent rinsing operation, likewise by spraying with de-ionised water, passing then to a step of drying of the containers and afterwards to a step of cutting off one end of the containers, which then pass to a gripping step, in the same number of containers that were arranged in the batch at the start of the method, these being inverted to permit the fall and collection of the masses of plasma.

Abstract: The gammaglobulin is extracted from a fraction isolated by fractionation with ethanol in the presence of a carbohydrate, and after reducing the content of contaminants with PEG, it is applied to an anionic resin exchange column, an effluent being obtained in which the PEG content is subsequently reduced by ultrafiltration and which is concentrated in order to carry out sequentially an optional treatment at an acid pH and at least one of the following steps of viral inactivation, consisting of pasteurisation and a treatment with solvent/detergent, the product afterwards being precipitated and washed with PEG in order to eliminate any chemical viral inactivation reagents and then, by solubilisation and change of pH, the protein contaminants, and finally purified by ultrafiltration to reduce the volume and the PEG content, then carrying out an optional virus filtration and subsequent concentration to a protein value of 5% or 10%.